To conduct a pharmacoeconomic analysis of oral drugs, tegafur vs capecitabine, for advanced colorectal cancer (CRC) in adult patients.
OBJECTIVE
To conduct a pharmacoeconomic analysis of oral drugs, tegafur vs capecitabine, for advanced colorectal cancer (CRC) in adult patients.
METHODS
Indirect comparison and network meta-analysis of clinical ef cacy and safety of tegafur vs capecitabine and tegafur + calcium folinate vs capecitabine were performed by authors. Cost-minimization analysis (CMA) with calculation of cost minimization difference was used for economic evaluation of studied drugs.
RESULTS
In RCT both tegafur + calcium folinate and capecitabine had a statistically signi cant advantage over 5- uorouracil + calcium folinate: the full and partial objective tumor response was achieved in more patients (table 1) . There was no statistically signi cant difference between oral tegafur, both in monotherapy or in combination with calcium folinate, and capecitabine for advanced CRC treatment in an indirect comparison (relative risk (RR) = 1,31, 95% CI [0,70; 2,48]) and network meta-analysis ( gure 1) of available studies [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] .
Capecitabine vs tegafur + calcium folinate had less 3-4th grade stomatitis but there was no difference in the incidence of diarrhea and 3-4th grade nausea/vomiting [1, [5] [6] [7] [8] [9] . There was no difference in safety between tegafur and capecitabine monotherapy in terms of incidence of diarrhea, vomiting, stomatitis/mucositis ( gure 2) [3, 4] . The hand-foot syndrome occurrred in less than 5% in case of tegafur [1, 5] .
Tegafur (in monotherapy or in combination with calcium folinate) is less costly than capecitabine. The difference in costs in favor of tegafur monotherapy amounted to €1,956.97 per 1 patient per 6 months or €3,778.53 per year; of tegafur + calcium folinate -€2,168.12 and €4,220.06 per 1 patient per 6 and 12 months, respectively (table 2).
DISCUSSION
Limitations of our study were the methodological shortcomings of RCT included in the network and indirect comparison. Tegafur RCT were made in 1980-90-s, which determined its insuf cient methodological quality when compared with modern standards. For example, we were not able to analyse overall survival and time to progression with the use of hazard ratio and its con dence interval, because it wasn't performed in tegafur studies. The current of side effects severity (NCIC CTC) also has not been applied at the time of tegafur monotherapy studies.
CONCLUSION
Tegafur seems to be a cost-saving option compared with capecitabine with similar ef cacy and safety. RCTs with direct comparison might provide better evidence of these two drugs comparative effectiveness. 
